CASE STUDY: Oral Semaglutide in a Young Diabetic = Weight Loss and CV Risk Reduction, Better Adherence and Treatment Comfort
Diabetologist MUDr. Tomáš Pfohl from the Regional Hospital Liberec illustrates the benefits of therapy with oral semaglutide in a relatively young diabetic patient with type 2 DM after unsatisfactory disease compensation was not achieved with a combination of gliptin and metformin.
The brief case study summarizes the main benefits of the treatment from the perspective of this particular patient (comfortable treatment without the need for injections, reduced appetite, weight loss, and overall better cooperation) as well as from the perspective of the physician (protection of beta cells, delay in the need for insulin, and comprehensive impact on CV risks).
Abbreviated information on the medicinal product Rybelsus® HERE
CZ24RYB00233
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
